Request a quote
or call us at (469) 786-6060
These partnerships are always win/win undertakings with the goal of providing better service to our clients, producing new intellectual property, and publication of important scientific data in high impact journals.
Some of our valued collaborators are:
NEW LIGANDS FOR RADIOPHARMACEUTICAL APPLICATIONS
MDS Nordion and Macrocyclics Inc. have entered into a research and development collaboration to develop innovative, bifunctional chelates for use in molecular imaging and targeted therapeutic pharmaceuticals in 2005. The collaboration is ongoing and has resulted in the discovery of several new ligands systems that are expected to accelerate the development of Cu-64 and Ga-68 PET imaging applications.
DEVELOPMENT OF NEW BIFUNCTIONAL LIGANDS FOR PET IMAGING WITH ZR-89
Macrocyclics and researchers at VU have been working on new bifunctional ligands designed specifically for the long-lived PET isotope Zr-89.
NANOPARTICLE BASED IMAGING PLATFORMS
Researchers at Washington University have developed a perfluorocarbon emulsified nanoparticle technology that can act as a platform for assembling antibodies imaging agents on surface of the particle vis lipophilic binding. As part of a collaborative study Macrocyclics designed novel phospholipid based MR contrast agents that bond to the nanoparticle through strong lipophilic interactions. The combination of antifibrin targeted antibodies and lipophilic contrast agent produced targeted nanoparticles that demonstrate significant T1-weighted image enhancement on the surface of blood clots.
DEVELOPMENT OF MULTIFUNCTIONAL MRI CONTRAST AGENTS FOR MOLECULAR IMAGING
Researchers at Yale and Macrocyclics are working together on research proposal aimed at developing a new family of MRI contrast agents that monitor multiple physiological events simultaneously.